Skip to main content
. 2017 Feb 1;8(10):16518–16530. doi: 10.18632/oncotarget.14965

Figure 4. JAS239 exhibits ChoKα inhibition and slows breast tumor growth.

Figure 4

(A) Treatment for 5 consecutive days with 2 mg/kg of MN58b (n = 4) or 4 mg/kg of JAS239 (n = 5) significantly reduced the growth rate of orthotopically-implanted 4175-Luc+ tumors, compared to control animals (n = 4). (B–E) The change in tCho (3.2 ppm) within MDA-MB-231 tumors was measured using MRS (B) to show progressive tCho increase during saline treatment (n = 5) (B, C), whereas reductions in tCho in response to 5 days of 2 mg/kg MN58b (n = 4) (B, D) or 4 mg/kg JAS239 (n = 3) (B, E) were observed. Values are reported as ± SEM, *indicates P < 0.05 compared to the control group.